Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Vertex Pharma upgraded at RBC Capital Markets (VRTX:NASDAQ)
RBC Capital Markets on Thursday upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Sector Perform, arguing that the Boston, Massachusetts-based biotech is poised to record upside in 2026 on the back of a cystic fibrosis franchise that…
Sun Pharma Is Said to Mull Bid for Women's Wellness Firm Organon
Sun Pharmaceutical Industries Ltd. is talking with advisers about a possible bid for New York-listed wellness company Organon & Co., according to people familiar with the matter. India's biggest pharmaceutical company, with a market capitalization…
Hudson pharma acquired by global investment firm
Proveris Scientific, a Hudson-based pharmaceutical product development firm, has been acquired by a subsidiary of Investindustrial, an international investment group with a U.S. office in New York City. Founded in 1995, Proveris provides testing…
'Tax evasion' by Ahmedabad pharma group, two arrested
The State GST Department in Gujarat Wednesday said it detected large-scale GST evasion by an Ahmedabad-based pharmaceutical group comprising 11 related entities engaged in pharma and chemical trading. “During coordinated search operations…
Pharmalittle: We're reading about Europe's pharma supply chain, stopping GLP-1 drugs, and more
Good morning, everyone, and welcome to the middle of the holiday-shortened week on this side of the pond. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After…
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC
Emerald Advisers LLC lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 29.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 720,343 shares…
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% - Should You Buy?
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) shot up 5.8% on Wednesday. The company traded as high as $8.63 and last traded at $8.58. 58,015 shares were traded during mid-day trading, a decline of 7% from the average session volume of…
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next?
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s stock price gapped down prior to trading on Wednesday. The stock had previously closed at $27.05, but opened at $26.00. Ascentage Pharma Group International…
Recursion Pharma at JPM26
Recursion Pharma presented at JP Morgan Healthcare 2026 and these are our highlights from their presentation. Recursion (RXRX) makes medicines out of a unified, AI-native intelligence platform that decodes complex science to find new gene targets…
US Futures, Global Markets Rally After Trump Greenland Pivot
US equity futures and global stocks are sharply higher as the S&P again marches toward a new ATH while the latest vol spike subsides, after Trump's tariff pivot eased geopolitical fears, though Greenland and other flashpoints mean the optimistic…
Vanguards of Health Care: Sofinnova Partners Betting on Data
“Despite all the noise — tariffs, regulation, geopolitics — the fundamentals are amazing, because our companies save people's lives and the demand for innovation is absolutely real.” says Antoine Papiernik, Sofinnova…
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential (NASDAQ:AMGN)
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, upwardly revised 2025 guidance, and healthy…
Alvotech: Why FDA Delays Don't Break The Bull Case (NASDAQ:ALVO)
Alvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033. It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. Even though it…
Dr Reddy's profit down 14% on low Lenalidomide US sales
In the October to December period of FY26, DRL recorded a 12 per cent Y-o-Y drop in revenue from North America to Rs 2,964 crore from Rs 3,383 crore due to continued price erosion in Lenalidomide. In contrast, revenue from India rose 19 per cent…
Nifty Jumps 180 Points, Sensex Up 0.7% In Opening As Donald Trump Eases EU Tariff Stance, Hopes Of India-US Deal Lift Sentiment
Nifty Jumps 180 Points, Sensex Up 0.7% In Opening As Donald Trump Eases EU Tariff Stance, Hopes Of India-US Deal Lift Sentiment | Image: ANI Domestic equity benchmarks opened higher on Thursday as investor confidence improved after US President…
Receive a Daily briefing on Pharma Industry News
Get Started